The spectrum of myelodysplastic syndromes post-solid organ transplantation: A single institutional experience

Menes, M.; Vakiani, E.; Keller, C.E.; Ho, E. K.; Colovai, A.; Nichols, G.; Diuguid, David L.; Mears, John Gregory; Vundavalli, Murty V.; Alobeid, Bachir; Bhagat, Govind

An increased incidence of acute myeloid leukemia (AML) has recently been documented in patients post-solid organ transplantation but the incidence and types of myelodysplastic syndromes (MDS) occurring in this patient population are not known. We identified 5 patients (3M, 2F, age 48–64 years) who developed MDS ranging from 1.8 to 25 years (median 4.2 years) post-solid organ transplantation, only 2 patients had received azathioprine. The cumulative incidence of MDS in heart and lung transplant recipients at 15 years was 0.5% and 1.8%, respectively, which is markedly higher compared to the general population. Low-risk types of MDS predominated, 3 of 5 patients are alive (median 3.9 years) since diagnosis. Deletions of chromosome 20q, which have not been previously reported in post-transplant MDS/AML, were identified in 3 cases. Our findings expand the morphologic and cytogenetic spectrum of MDS occurring post-solid organ transplantation and suggest that mechanisms beside azathioprine toxicity might be important in disease pathogenesis.


  • thumnail for Menes M et al Leu Res 2007.pdf Menes M et al Leu Res 2007.pdf application/pdf 102 KB Download File

Also Published In

Leukemia Research

More About This Work

Academic Units
Pathology and Cell Biology
Published Here
February 12, 2020